Senovia Biosciences
Senovia Biosciences is developing pharmaceutical therapies that aim to modulate metabolic state as a core variable in the treatment of diverse diseases. The company's mission is to restore health by controlling metabolic state rather than focusing exclusively on molecular targets, supported by published evidence across neurology, psychiatry, oncology, cardiology, immunology, and infectious disease. Senovia applies a unified platform approach—Metabolic State Medicine—to address bioenergetic dysfunction, serving as an upstream driver for multiple chronic conditions. Its programs serve several high unmet-need indications and are built on a platform of state actuators: oral medicines designed to achieve, titrate, and sustain specific metabolic states safely for chronic use, without dietary restriction.
Industries
Nr. of Employees
small (1-50)
Products
SNV-401 (Drug-Resistant Epilepsy)
Oral prodrug designed to achieve sustained, therapeutic ketosis for patients with drug-resistant epilepsy, providing anti-seizure effects via multiple pathways without dietary restriction.
SNV-201 (Alzheimer’s Disease & Neurodegeneration)
Oral prodrug to restore brain energy metabolism via pharmaceutical-grade ketone delivery, targeting cognitive impairment in Alzheimer's and related neurodegenerative disorders.
SNV-801 (Heart Failure)
Metabolic inotrope designed for heart failure through direct oral delivery of ketone body exposure, with validated hemodynamic and biomarker endpoints.
SNV-601 (Immuno-Oncology)
Oral metabolic agent to rescue anti-tumor T-cell function by addressing energy deficit in the tumor microenvironment; designed as an adjuvant or combination in immuno-oncology.
SNV-301 (Serious Mental Illness)
Oral therapy to correct bioenergetic deficits in treatment-resistant psychiatric conditions, associated with improvement in multiple diagnostic categories through multi-pathway engagement.
SNV-701 (Autoimmune Disease)
Oral therapy for autoimmune disorders based on multi-node immunomodulation via metabolic state control; designed for indications with partial response to biologics.
SNV-401 (Drug-Resistant Epilepsy)
Oral prodrug designed to achieve sustained, therapeutic ketosis for patients with drug-resistant epilepsy, providing anti-seizure effects via multiple pathways without dietary restriction.
SNV-201 (Alzheimer’s Disease & Neurodegeneration)
Oral prodrug to restore brain energy metabolism via pharmaceutical-grade ketone delivery, targeting cognitive impairment in Alzheimer's and related neurodegenerative disorders.
SNV-801 (Heart Failure)
Metabolic inotrope designed for heart failure through direct oral delivery of ketone body exposure, with validated hemodynamic and biomarker endpoints.
SNV-601 (Immuno-Oncology)
Oral metabolic agent to rescue anti-tumor T-cell function by addressing energy deficit in the tumor microenvironment; designed as an adjuvant or combination in immuno-oncology.
SNV-301 (Serious Mental Illness)
Oral therapy to correct bioenergetic deficits in treatment-resistant psychiatric conditions, associated with improvement in multiple diagnostic categories through multi-pathway engagement.
SNV-701 (Autoimmune Disease)
Oral therapy for autoimmune disorders based on multi-node immunomodulation via metabolic state control; designed for indications with partial response to biologics.
Expertise Areas
- Metabolic state therapeutics
- Drug development for bioenergetic dysfunction
- Clinical trial stratification by metabolic biomarkers
- Multi-pathway mechanism pharmacology
Key Technologies
- Pharmaceutical-grade ketone body delivery
- Biomarker-driven patient stratification
- Metabolic state actuators
- NLRP3 inflammasome inhibition